Bhardwaj, Nina http://orcid.org/0000-0003-1865-4187
Friedlander, Philip A.
Pavlick, Anna C.
Ernstoff, Marc S. http://orcid.org/0000-0002-8132-7069
Gastman, Brian R.
Hanks, Brent A.
Curti, Brendan D.
Albertini, Mark R.
Luke, Jason J.
Blazquez, Ana B.
Balan, Sreekumar http://orcid.org/0000-0002-2092-5145
Bedognetti, Davide
Beechem, Joseph M.
Crocker, Andrea S.
D’Amico, Leonard
Danaher, Patrick http://orcid.org/0000-0002-2844-5883
Davis, Thomas A.
Hawthorne, Thomas
Hess, Bruce W.
Keler, Tibor
Lundgren, Lisa
Morishima, Chihiro
Ramchurren, Nirasha
Rinchai, Darawan http://orcid.org/0000-0001-8851-7730
Salazar, Andres M.
Salim, Bob A.
Sharon, Elad
Vitale, Laura A.
Wang, Ena
Warren, Sarah
Yellin, Michael J.
Disis, Mary L.
Cheever, Martin A.
Fling, Steven P. http://orcid.org/0000-0001-6263-0153
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA201189, R01CA180913, 1U01CA154967, P30 CA015704, 1U01CA154967, P30 CA015704)
Article History
Received: 23 August 2019
Accepted: 14 October 2020
First Online: 16 November 2020
Competing interests
: A.S.C., T.H., T.K., L.A.V., T.A.D. and M.J.Y. are/were employed by and are stockholders in Celldex Therapeutics; J.M.B., P.D. and S.W. are employed by NanoString Technologies; A.M.S. is employed by Oncovir; N.B. and J.J.L. receive research support from Celldex (and Oncovir N.B.). L.D., L.L., N.R., B.W.H., M.A.C. and S.P.F. are employed by the Fred Hutchinson Cancer Research Center, which received partial funding from Celldex for this trial.